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Abstract
OBJECTIVES—To determine whether a treating oncologist’s characteristics are associated with 
variation in use of chemotherapy for patients with advanced non–small cell lung cancer (aNSCLC) 
at the end of life.
STUDY DESIGN—Retrospective cohort.
METHODS—Using the 2009 Surveillance, Epidemiology, and End Results–Medicare database, 
we studied chemotherapy receipt within 30 days of death among Medicare enrollees who were 
diagnosed with aNSCLC between 1999 and 2006, received chemotherapy, and died within 3 years 
of diagnosis. A multilevel model was constructed to assess the contribution of patient and 
physician characteristics and geography to receiving chemotherapy within 30 days of death.
RESULTS—Among 21,894 patients meeting eligibility criteria, 43.1% received chemotherapy 
within 30 days of death. In unadjusted bivariate analyses, female sex, Asian or black race, older 
age, and a greater number of comorbid diagnoses predicted lower likelihood of receiving 
chemotherapy at the end of life (P ≤.038 for all comparisons). Adjusting for patient and physician 
characteristics, physicians in small independent practices were substantially more likely than those 
employed in other practice models, particularly academic practices or nongovernment hospitals, to 
order chemotherapy for a patient in the last 30 days of life (P <.001 for all comparisons); female 
physicians were less likely than males to prescribe such treatment (P = .04).
CONCLUSIONS—Patients receiving care for aNSCLC in small independent oncology practices 
are more likely to receive chemotherapy in the last 30 days of life.
Despite a half century of treatment advances, lung cancer—the most common solid tumor in 
the United States—remains among the cancers least responsive to treatment.1 A majority of 
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patients are diagnosed at an advanced stage and, even with the newest therapies, barely 1 in 
10 are alive a year after diagnosis.2,3 In the final weeks of life, many patients with advanced 
non–small cell lung cancer (aNSCLC) undergo aggressive treatment that can include 
repeated emergency department visits, prolonged hospitalizations, intensive care, and 
additional lines of chemotherapy that contravene guidelines.4–8 Attendant effects on quality 
of life are well documented, and the value of such expensive treatment is debated in the lay, 
clinical, and policy realms.9–11
Why aggressive end-of-life treatment occurs is not clearly understood. Regional variations in 
the aggressiveness of cancer treatment have been well established and patient factors have 
been explored12,13; however, the degree of variation between individual physicians is not 
known.14,15 We conducted this study to determine the extent to which physician 
characteristics explain patients’ receipt of chemotherapy in the 30 days prior to death among 
patients with aNSCLC.
METHODS
Sources of Data
We used the 2009 Surveillance, Epidemiology, and End Results (SEER) cancer registry and 
linked Medicare claims16 to identify patients and describe treatment patterns. SEER regions 
include 28% of the US population. Approximately 68% of lung cancers diagnosed in SEER 
regions are in Americans older than 65 years.2 Using the Unique Physician Identification 
Number Registry, we linked the physician submitting a Medicare claim to their 
characteristics in the American Medical Association (AMA) Masterfile.17
Study Cohort
The Figure details the initial sample and number of patients dropped due to each exclusion 
criterion. We first identified all patients in the SEER registry diagnosed with lung cancer 
between 1999 and 2006. We selected 1999 due to changes in physicians’ unique 
identification codes that year and 2006 to allow for up to 3 years of data after diagnosis. We 
limited the sample to those 65 years or older at diagnosis who were enrolled in traditional 
Medicare Part A and Part B from at least 12 months prior to a first diagnosis of lung cancer 
until 3 years after diagnosis or until death. Patients with other incident cancers were 
excluded to avoid erroneously counting chemotherapy directed toward another cancer.
Among 193,200 subjects satisfying all conditions (ie, lung cancer, age ≥65, continuous 
enrollment in Medicare A and B, no other cancer), we excluded 4518 subjects who died on 
unknown dates and 123 subjects with charges for chemotherapy after their recorded date of 
death. Our cohort was then limited to 155,794 patients with stage 3b or 4 aNSCLC; an 
additional 38,311 were excluded for diagnosis dates out of range. We excluded 89,069 who 
had not received chemotherapy within 3 years of initial diagnosis and compared their 
characteristics with those who received chemotherapy. To avoid insufficient data biasing 
interpretation of physicians’ practice patterns, subjects were excluded if not treated by an 
identifiable oncologist who provided care to 5 or more patients in the sample. In sensitivity 
analyses, we evaluated the impact of physician characteristics on receipt of chemotherapy in 
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the last 30 days of life for all physicians, irrespective of the number of patients seen, and 
physicians with 10 or more patients. Our final analytic sample comprised 21,894 aNSCLC 
subjects.
Construction of the Dependent Variable
Chemotherapy use was established by Medicare charges in outpatient, inpatient, or 
physician claims for chemotherapy-related encounters (International Classification of 
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnosis codes V58.1, V66.2, 
and V67.2), chemotherapy administration (ICD-9-CM procedure code 99.25; Current 
Procedural Terminology codes 96400–96549; Health Care Common Procedure Coding 
System codes J8530, J8560, J8600, J8610, J8999, Q0083–Q0085, and G0921–G0932; and 
Revenue Center Codes 0331, 0332, and 0335), or chemotherapy agents (J Codes other than 
diethylstilbestrol and leuprolide). The primary outcome was whether a patient who ever 
received chemotherapy received a final dose during the last 30 days of life.
Patient–Physician Link
Administration of chemotherapy at the end of life was attributed to the oncologist submitting 
a Medicare claim with the latest date of service rendered prior to a patient’s death. 
Sensitivity analysis was performed, attributing the patient to the oncologist with the most 
visits. Physicians were considered oncologists if the billing physician’s specialties in either 
Medicare claims or AMA-linked physician files included oncology, hematology-oncology, 
or hematology.
Independent Variables
Patient were classified by race (white, black, Hispanic, Asian, other), sex, age at diagnosis 
(65–69, 70–74, 75–79, 80–84, ≥85 years), last known marital status, median income by zip 
code (by quartile, as a proxy for socioeconomic status), and year of diagnosis. Time between 
diagnosis and last chemotherapy was calculated and grouped (<1, 1, 2–3, 4–5, 6–7, 8–9, 10–
11, 12–23, 24–36 months), as it was hypothesized that a recent diagnosis might be 
associated with receiving treatment at the end of life. We also included the proportion of 
blacks in the patient’s residential zip code and birthplace outside of the United States.
We calculated a modified Charlson Comorbidity Index score for each patient using ICD-9-
CM–coded diagnoses from inpatient claims, carrier claims, and outpatient claims using the 
Wang method.18 In order to approximate patients’ health leading up to death, comorbidity 
scores were calculated from claims for services provided during the 12 months prior to the 
month of death.
Physician characteristics included in the model were sex and year that medical training was 
completed. Age was strongly correlated with year of training completion and thus excluded. 
We examined the type of practice based on the present employer variable from the AMA 
Masterfile and classified this variable into 6 categories: small independent (physician-
owned, 1–2 physicians), group practice (physician-owned, >2 physicians), government 
(employed by city, county, state, or federal government), academic (employed by medical 
schools), hospital (employed by non–government-owned hospital), and other.
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As there is good evidence supporting geographic variations in treatment practices, we sought 
to control for such variation based on SEER registry sites; however, because of its size and 
previously demonstrated practice variation,12 California was split by county into 4 zones: 
Los Angeles, non-LA Metro-South (San Diego, Riverside, San Bernardino, Orange, 
Ventura), Metro-North (San Francisco, Alameda, Santa Clara, Contra Costa, San Mateo, 
Marin), and Other. Rural Georgia, with just 47 eligible cases, was combined with Atlanta, 
yielding a single site for all of Georgia. SEER sites were otherwise categorized according to 
the SEER 17 registry.19
Statistical Analysis
Frequency distributions were calculated for patient, oncologist, and geographic variables. 
We used a multilevel logistic regression mixed model with dichotomous outcomes to 
estimate the probability of receiving chemotherapy treatment in the last 30 days of life. 
Patients were nested within physicians, who, in turn, were nested within geographic 
locations (SEER site, modified as above) as a random intercept at the highest level. The 
model adjusted for the patient and physician covariates, as described above. To facilitate 
interpretation of the magnitude of the effects, adjusted relative risks are presented along with 
the coefficient estimates and P values from the regression.
To calculate the marginal effect of the physician’s type of practice on receiving 
chemotherapy at the end of life, each patient’s probability of receiving treatment was 
recalculated as if all received treatment under a uniform type of practice, adjusting for 
patient variables and other physician variables. This was repeated for each type of practice.
University of California, Los Angeles, Institutional Review Board approved the study.
RESULTS
We identified 23,687 continuously enrolled Medicare (parts A and B) patients diagnosed 
with aNSCLC between 1999 and 2006. Table 1 shows the distribution of patient 
characteristics and associated probability of receiving chemotherapy within 30 days of 
death, among the 21,894 (92.4%) patients receiving chemotherapy within 3 years of 
diagnosis. Of these, 9447 (43.1%) received chemotherapy within 30 days of death.
In bivariate analyses, men were more likely than women to receive chemotherapy near the 
end of their lives (45.9% vs 39.5%; P <.001) (Table 1). Patients were less likely to receive 
chemotherapy at the end of life if they were Asian (33.3%) or black (40.0%) compared with 
whites (43.9%; P <.001), older (40.8% among those aged ≥85 vs 44.4% among those aged 
65–69; P = .04), had more comorbidities (P = .001), or diagnosed in 2005 (37.8%) or 2006 
(37.5%) compared with 1999 (43.9%) (P <.001). Despite these differences in treatment, 
none of these variables were associated with a difference in survival (data not shown).
Characteristics of the 89,069 patients excluded for nonreceipt of chemotherapy matched 
closely on race, sex, year of diagnosis, and SEER site categories. Younger patients and those 
with low comorbidity scores were more likely to have started chemotherapy than those who 
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were older and sicker; females were slightly more likely than males to have never received 
chemotherapy.
Physician characteristics and the numbers of patients attributed to physicians with each 
characteristic are shown in Table 2. Oncologists were primarily male (77.4%) and in group 
practices (61.2%). Physicians in small independent practices were significantly more likely 
to administer chemotherapy during the last 30 days of life (Table 2). Adjusting for all patient 
and provider covariates, the predicted probability of receiving chemotherapy in the last 30 
days of life was 1.4-fold greater (0.56) for patients receiving care in small independent 
practices relative to those seeing oncologists in academic centers (0.40; P <.001) (Table 3). 
Predicted probabilities for patients receiving care in group practices, government facilities, 
hospitals, and other types of practice, were 0.55, 0.46, 0.42, and 0.52, respectively. Female 
oncologists were significantly less likely to administer chemotherapy at end of life (P <.
001). Magnitude and direction of predictors were not meaningfully changed when analyses 
were repeated for patients of physicians treating at least 10 patients.
Adjusting for other patient and physician characteristics, the predicted probabilities of 
receiving chemotherapy in the last 30 days of life were lower for blacks, women, and those 
75 years or older, diagnosed in 2005 or 2006 (vs 1999), for whom 2 or more months had 
elapsed since diagnosis, and with comorbidity scores of 3 to 5 or 6 to 8. Even within these 
subgroups, at least one-third would have been predicted to receive chemotherapy in the last 
30 days of life (Table 3). Marital status and zip code–level median income categories were 
not significant predictors of chemotherapy receipt at end of life.
Overall, the model explained 28.9% of variation in chemotherapy use in the last 30 days of 
life among patients who were being treated for aNSCLC. Geographic location of care was a 
significant fixed-effects parameter (P <.001) and accounted for 16% of variation in 
chemotherapy use at the end of life. Patient characteristics accounted for 5.8%, while 
physician characteristics accounted for 7.1% of explained variation in chemotherapy use in 
the last 30 days of life.
DISCUSSION
Advanced cancer is emotionally and physically taxing and can cause a great deal of 
suffering. Although patients are concerned about both quality and quantity of life,20 most 
prefer not to undergo aggressive treatment at life’s end,21 making it particularly important 
that they understand expected clinical outcomes from treatment. Yet, Weeks et al found that 
69% of patients with advanced lung cancer believed that they had some chance of cure.22 
Physician guidance regarding goals of care, prospective benefits of therapy, and helping to 
determine whether benefits are likely to outweigh expected side effects are critical 
components of quality care.
Physician prognostication is inexact, however, and variations in practice may reflect this 
uncertainty to some extent. Healthcare practices are known to vary—sometimes 
substantially—by geographic region or hospital12; few studies have examined whether 
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physician characteristics are associated with variation in difficult clinical decisions, such as 
whether to continue therapy in the face of declining health.
Although the optimal rate of chemotherapy use at the end of life is unknown, our data 
suggest that nonclinical factors may strongly influence treatment decisions. In our study, 
43% of chemotherapy recipients received final doses in the 30 days prior to death. Patients 
were much more likely to receive late chemotherapy if their physician was in a small 
independent practice or in a group practice. Of note, physicians in these types of practice 
were responsible for the care of almost three-fourths of all patients with aNSCLC. Since 
2008, the ranks of community oncologists have dwindled,23 and there has been a migration 
toward larger group practices.24 Chemotherapy use at the end of life has trended downward 
during this same period, but it is not known whether these events are correlated or 
coincidental.
The data do not allow us to conclude why the type of practice is associated with 
chemotherapy use at the end of life. Many factors are likely to be associated, including 
differences in practice style—such as attitudes toward aggressive treatment, perceptions of 
the benefit of treatment, and the desire to provide hope to patients—and financial incentives 
for providing more treatment. Physicians in different types of practices may also see patients 
with diverse expectations and preferences for care, perhaps because patients seeking more 
aggressive treatment self-select physicians willing to provide that care.
Even for patients desiring aggressive treatments, physicians have a duty to provide treatment 
only to those who may reasonably be expected to benefit. Increased age and significant 
comorbid illness decrease the already limited benefits of late chemotherapy; our findings of 
there being a lower likelihood of these populations initiating chemotherapy suggest that 
appropriate clinical factors are playing some role in treatment decisions. Aggressive 
treatment also comes at great financial expense. Treatment of stage 4 aNSCLC is associated 
with particularly low value: $1.19 million per year of life saved.25 Some commentators 
envision a “geriatric blast for oncologists” as more Baby Boomers become Medicare-
eligible,26 but humanistic and financial imperatives underline a need to reevaluate aggressive 
care for advanced cancers.27
Our study confirms aspects of others’ work—generally conducted in a more heterogeneous 
group of cancers—while adding several important dimensions to the literature. Earle found 
that 15.7% of patients who start chemotherapy received a dose within 14 days of death.28 
We confirm even higher rates in the last 30 days of life, specifically among those with 
aNSCLC. We also reaffirm geographic variation previously noted.
Our findings that physician characteristics predict patterns of care for aNSCLC patients at 
the end of life contribute a unique dimension to existing literature. Setoguchi, studying 
quality indicators in end-of-life care for lung, colorectal, breast, and prostate cancers in New 
Jersey (a SEER site with high treatment rates at the end of life12) and Pennsylvania (not in 
SEER, average end-of-life rates) noted that oncologists in small group practices were more 
likely to administer chemotherapy and less likely to initiate hospice than those in large 
groups.29 Our geographically broader study examined a specific cancer in advanced stage 
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that responds to chemotherapy only to a limited extent. Controlling for geographic variation, 
we nonetheless found meaningfully higher rates in small independent practices and among 
male physicians. As others have noted, we found that chemotherapy receipt within 30 days 
of death decreased in 2005, corresponding with the substantial decline in reimbursement by 
Medicare for providing outpatient chemotherapy, as well as FDA approval of an oral therapy 
(erlotinib), not included in our dataset.30
Limitations
This study has several limitations. Retrospective analysis of administrative data does not 
allow us to distinguish between aggressive treatment that is patient-driven from that which is 
physician-driven. It is possible that patients desiring aggressive treatment seek out 
physicians amenable to their demands, although this would not invalidate the observation 
that oncologists treating at higher rates gravitate to small independent practices. As our data 
were limited to Medicare patients living within SEER regions, and analysis was limited to 
1999 to 2006 diagnoses, results may not be generalizable to other populations or time 
periods. Data sources limited the availability of physician demographics, practice 
characteristics, and the ability to distinguish among practices with more than 2 physicians. 
That so few measures explained more variation (7.1%) than the robust demographic data 
available for patients (5.8%) suggests that other physician characteristics may warrant 
exploration; parameters of interest might include physician wealth, marital status, and race, 
practice payer mix, and training environment. Assignment of responsibility to the last 
oncologist seen may incorrectly attribute final doses of chemotherapy, although this is 
unlikely to introduce bias regarding type of practice. Our study design did not permit 
inclusion of oral chemotherapeutic agents (eg, erlotinib), possibly used by a subset of 
patients during later parts of the observation period, but whose inclusion could only have 
increased treatment rates near death.
CONCLUSIONS
The disconnect between how patients report preferring care at the end of life and how they 
actually die may have any number of causes, including clinical uncertainty, poor 
prognostication, incomplete sharing of information with patients, misguided optimism, or 
physicians’ failure to explore patients’ preferences. Poor communication of information is 
notorious and pervasive. When two-thirds of patients with stage 4 lung cancer are unaware 
that chemotherapy is unlikely to cure their cancer and, therefore, they do not know they are 
approaching the end of life,22 surely fewer know that late aggressive therapy may actually 
foreshorten life.31,32
Improved communication and early incorporation of palliative care can lead to care more 
consistent with patients’ goals. Early enrollment in palliative care is associated with a 
significant decrease in receipt of chemotherapy close to death when chemotherapy’s side 
effects outweigh any potential benefit.33 Better tools are needed to help oncologists 
determine how to communicate prognoses in ways that patients can understand, as well as 
how best to partner with patients in shared decision making when a prognosis is poor. 
Together, these would help determine when to advise a patient to avoid the risks and 
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discomforts of chemotherapy, and instead enjoy what quality can be had during the limited 
remaining life.
Prognosticative limitations notwithstanding, variable rates of late chemotherapy receipt 
signify inconsistency in how cancer is treated as death nears. As variations in practice are 
also a cost driver, evidence of variation between physicians suggests the need to improve 
physician acceptance of the responsibility to more judiciously steward resources or, failing 
that, institute policies and practice guidelines to minimize variations in care.
When caring for people with advanced disease, an important aim of medicine includes 
helping patients experience death on their own terms. The present study provides some 
support for the common and long-held suspicion that our healthcare system may not always 
guide patients toward the best choices. Future efforts to improve the experiences of patients 
with advanced disease may be dampened by the extent to which variation and potential 
overtreatment are due to the unintended and untoward effects of forces influencing physician 
decisions. For the time being, it is important for patients to be aware that characteristics of 
their physician and where they receive care might strongly influence the care they receive.
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TAKEAWAY POINTS
Oncologists’ characteristics explain significant variation in patients’ receipt of 
chemotherapy in the last 30 days of life:
❯ Patients should understand the variation in practices among oncologists 
treating the same condition.
❯ Awareness of such variation may influence an individual oncologist’s 
practice decisions and eventually lead to consensus practices at end of life; 
practices may already have changed since the period under study.
❯ Less variation is likely to yield better alignment between patient goals and 
treatment received, and result in higher value care at the end of life.
❯ Payers may wish to consider oncologist practice type in determining network 
participation.
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FIGURE. 
Patients With Lung Cancer Dropped Due to Exclusion Criteria
AMA indicates American Medical Association; HMO, health maintenance organization; 
NSCLC, non–small cell lung cancer.
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TABLE 1
Baseline Characteristics and Probability of Patients With Advanced Non–Small Cell Lung Cancer Receiving 
Chemotherapy Within 30 Days of Death
Variables N (%)
Received Chemotherapy
Within 30 Days of Death
Yes (%) P
Total N 21,894 43.1
Race/ethnicity
  White 18,631 (85.1) 43.9 <.001
  Black 1676 (7.7) 40.0
  Hispanic 675 (3.1) 43.1
  Asian 867 (4) 33.3
  Other 45 (0.2) 40.0
Sex
  Male 12,529 (57.2) 45.9 <.001
  Female 9365 (42.8) 39.5
Age, years
  65–69 5431 (24.8) 44.4 .038
  70–74 6934 (31.7) 43.3
  75–79 5863 (26.0) 43.0
  80–84 2879 (13.1) 41.5
  ≥85 787 (3.6) 40.8
Year of diagnosis
  1999 1144 (5.2) 43.9 <.001
  2000 2585 (11.8) 46.5
  2001 2727 (12.5) 46.2
  2002 2931 (13.4) 47.2
  2003 3304 (13.9) 43.8
  2004 3166 (14.5) 43.4
  2005 3182 (14.5) 37.8
  2006 2855 (13.0) 37.5
Comorbidity scorea
  0–2 17,928 (81.9) 42.6 .001
  3–5 3458 (15.8) 45.0
  6–8 463 (2.1) 49.5
  ≥9 45 (0.2) 57.8
Months: diagnosis to last treatment
  <1 709 (3.2) 59.9 <.001
  1 2486 (11.4) 56.6
  2–3 5334 (24.4) 47.1
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Variables N (%)
Received Chemotherapy
Within 30 Days of Death
Yes (%) P
  4–5 3642 (16.6) 39.8
  6–7 2387 (10.4) 39.7
  8–9 1544 (7.1) 44.2
  10–11 1052 (4.8) 40.9
  12–23 3253 (14.9) 38.1
  24–35 1487 (6.8) 23.5
SEER site, states/regions
  California - Los Angelesb 1513 (6.9) 45.4 <.001
  California - Metro-Southb 1546 (7.1) 46.1
  California - Metro-Northb 961 (4.4) 32.5
  California - Otherb 2512 (11.5) 42.9
  Connecticut 1709 (7.8) 42.4
  Detroit 2089 (9.5) 45.5
  Georgiac 850 (3.9) 52.1
  Hawaii 290 (1.3) 32.1
  Iowa 1573 (7.2) 37.8
  Kentucky 1976 (9.0} 40.3
  Louisiana 1517 (6.9) 40.5
  New Jersey 3434 (15.7) 48.1
  New Mexico 361 (1.6) 39.9
  Seattle 1266 (5.8) 42.3
  Utah 297(1.4) 37.7
a
Based on records for 12 months prior to the month of death.
bCalifornia is 1 Surveillance, Epidemiology, and End Results (SEER) site; due to its size, it was partitioned.
c
Rural Georgia SEER site had just 49 cases and was combined with Atlanta into “Georgia.”
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TABLE 3
Predicted Probabilities for Receipt of Chemotherapy in the Last 30 Days of Lifea,b
Patient Variables
Predicted
Probability (%) Pb
Relative
Risk
Bootstrapped
95% CI
Race
  White 0.40 – 1.00
  Asian 0.34 .01 0.84 (0.77–0.99)
  Black 0.36 .01 0.90 (0.85–0.97)
  Hispanic 0.38 .48 0.96 (0.85–1.07)
  Other 0.29 .17 0.71 (0.34–1.23)
Gender
  Male 0.42 – 1.00
  Female 0.36 <.001 0.86 (0.84–0.89)
Age at diagnosis, years
  65–69 0.42 – 1.00
  70–74 0.40 .12 0.96 (0.91–1.02)
  75–79 0.39 .01 0.93 (0.86–0.98)
  80–84 0.36 <.001 0.86 (0.79–0.92)
  >85 0.34 <.001 0.80 (0.73–0.91)
Marital status at diagnosis
  Married 0.39 – 1.00
  Single 0.39 .75 1.02 (0.90–1.08)
  Divorced 0.39 .57 0.99 (0.89–1.00)
  Widowed 0.40 .53 1.02 (0.96–1.08)
  Unknown 0.39 .72 0.99 (0.84–1.13)
Year diagnosed
  1999 0.41 – 1.00
  2000 0.42 .45 1.04 (0.93–1.16)
  2001 0.41 .97 1.00 (0.87–1.07)
  2002 0.44 .15 1.07 (0.96–1.14)
  2003 0.40 .83 0.99 (0.89–1.09)
  2004 0.40 .60 0.98 (0.86–1.06)
  2005 0.35 .001 0.84 (0.73–0.94)
  2006 0.34 <.001 0.83 (0.75–0.92)
Zip code–level median income (quartile)
  0%–24% 0.38 – 1.00
  25%–49% 0.39 .35 1.03 (0.98–1.09)
  50%–74% 0.40 .33 1.05 (0.99–1.15)
  75%–99% 0.40 .32 1.06 (0.98–1.14)
  Unknown 0.41 .31 1.08 (0.96–1.21)
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Patient Variables
Predicted
Probability (%) Pb
Relative
Risk
Bootstrapped
95% CI
Months since diagnosis
  <1 0.54 – 1.00
  1 0.51 .18 0.94 (0.85–1.04)
  2–3 0.42 <.001 0.78 (0.73–0.83)
  ≥4 0.35 <.001 0.65 (0.63–0.69)
Comorbidity score
  0–2 0.41 – 1.00
  3–5 0.38 <.001 0.92 (0.89–0.96)
  6–8 0.37 <.001 0.91 (0.85–0.98)
  ≥9 0.35 .15 0.85 (0.67–1.07)
Physician variables
  Sex
    Male 0.54 – 1.00
    Female 0.52 .01 0.95 (0.90–0.99)
  Type of practice
    Academic 0.40 – 1.00
    Small independent 0.56 <.001 1.40 (1.21–1.60)
    Group (>2) 0.55 <.001 1.35 (1.17–1.59)
    Hospital (nongovernment) 0.42 .72 1.04 (0.84–1.21)
    Government 0.46 .13 1.14 (0.93–1.36)
    Other 0.52 .001 1.29 (1.05–1.52)
  Decade trained
    2000s 0.54 – 1.00
    1990s 0.54 .94 0.99 (0.93–1.08)
    1980s 0.54 .98 0.99 (0.94–1.07)
    1970s 0.55 .75 1.01 (0.96–1.13)
    Before 1970 0.51 .47 0.95 (0.88–1.12)
    Unknown 0.52 .47 0.96 (0.87–1.10)
  Geographic site
    New Jersey 0.43 – 1.00
    California - Los Angeles 0.43 .97 0.99 (0.94–1.05)
    California - Metro-South 0.43 .99 0.99 (0.92–1.04)
    California - Metro-North 0.32 <.001 0.79 (0.71–0.86)
    California - Other 0.40 .09 0.94 (0.87–1.02)
    Connecticut 0.39 .10 0.94 (0.87–1.01)
    Detroit 0.41 .44 0.97 (0.90–1.04)
    Georgia 0.50 .002 1.13 (1.07–1.20)
    Hawaii 0.31 .008 0.78 (0.63–0.93)
    Iowa 0.32 <.001 0.79 (0.73–0.84)
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Patient Variables
Predicted
Probability (%) Pb
Relative
Risk
Bootstrapped
95% CI
    Kentucky 0.35 <.001 0.86 (0.78–0.93)
    Louisiana 0.39 .06 0.92 (0.87–1.04)
    New Mexico 0.35 .03 0.86 (0.70–0.98)
    Seattle 0.39 .14 0.94 (0.89–1.02)
    Utah 0.34 .02 0.83 (0.72–0.95)
CI indicates confidence interval.
a
These are patients who were in the Surveillance, Epidemiology, and End Results-Medicare Claims Data based on records for 12 months prior to 
the month of death; only physicians treating 5 or more patients.
bA multilevel logistic regression mixed model was used to estimate the probability of receiving chemotherapy treatment in the last 30 days of life. 
A random intercept model was used with patients nested within physicians, who, in turn, were nested within geographic locations. P values were 
derived from these respective models.
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